Eris Lifesciences Intrinsic Value
Eris Lifesciences intrinsic value. Eris Lifesciences (ERIS) median intrinsic value is ₹2658.00 from 10 valuation models (range ₹399–₹3323), vs current price ₹1329.00 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse ERIS financial statements for revenue, profit, balance sheet and cash flow data.
ERIS Valuation Methods Summary — DCF, Graham Number & P/E
Eris Lifesciences intrinsic value across 10 models vs current price ₹1329.00 — upside/downside and value range per method. Analyse Eris Lifesciences shareholding analysis to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1166.88 | ₹933.50 - ₹1400.26 | -12.2% | EPS: ₹53.04, Sector P/E: 22x |
| Book Value Method | asset | ₹3322.50 | ₹2990.25 - ₹3654.75 | +150.0% | Book Value/Share: ₹2782.86, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2658.00 | ₹2392.20 - ₹2923.80 | +100.0% | Revenue/Share: ₹2551.43, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2658.00 | ₹2392.20 - ₹2923.80 | +100.0% | EBITDA: ₹1092.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3322.50 | ₹2658.00 - ₹3987.00 | +150.0% | CF Growth: 9.2%, Discount: 15% |
| PEG Ratio Method | growth | ₹398.70 | ₹358.83 - ₹438.57 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹819.47 | ₹737.52 - ₹901.42 | -38.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2658.00 | ₹2392.20 - ₹2923.80 | +100.0% | ROE: 19.2%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1822.38 | ₹1640.14 - ₹2004.62 | +37.1% | EPS: ₹53.04, BVPS: ₹2782.86 |
| Dividend Yield Method | dividend | ₹398.70 | ₹358.83 - ₹438.57 | -70.0% | DPS: ₹7.21, Target Yield: 2.5% |
ERIS Intrinsic Value vs Market Price — All Valuation Models
Eris Lifesciences fair value range ₹399–₹3323 vs current market price ₹1329.00 across 10 valuation models. For current market price and key ratios, visit Eris Lifesciences share price today.
ERIS Intrinsic Value Analysis — Undervalued or Overvalued?
Eris Lifesciences median intrinsic value ₹2658.00, current price ₹1329.00 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of ERIS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Eris Lifesciences (ERIS) is ₹2658.00 (median value). With the current market price of ₹1329.00, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹398.70 to ₹3322.50, indicating ₹398.70 - ₹3322.50.
Is ERIS undervalued or overvalued?
Based on our multi-method analysis, Eris Lifesciences (ERIS) appears to be trading below calculated value by approximately 100.0%.
ERIS Financial Health — Key Ratios vs Industry Benchmarks
Eris Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 19.2% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 30.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.48x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
ERIS Cash Flow Quality — Operating & Free Cash Flow
Eris Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹538 Cr | ₹353 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹1,065 Cr | ₹1,026 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹486 Cr | ₹-428 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹292 Cr | ₹-196 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹378 Cr | ₹218 Cr | Positive Free Cash Flow | 8/10 |